hypersensitivity to the components of the drug,
gout,
urolithiasis,
arrhythmias,
chronic kidney failure,
children under 3 years of age (body weight up to 15-20 kg).
Immunosuppressants can reduce the effectiveness of the drug. Xanthine oxidase inhibitors and uricosuric agents (including diuretics) may contribute to the risk of increased serum uric acid levels in patients taking Isoprinosine.
From the gastrointestinal tract: often — nausea, vomiting, epigastric pain, sometimes-diarrhea, constipation.
often-a temporary increase in the activity of transaminases and alkaline phosphatase in the blood plasma, an increase in the concentration of urea in the blood plasma.
From the urinary system:
often-joint pain, exacerbation of gout.
By prescription.
After 2 weeks of use of Isoprinosine, the concentration of uric acid in the blood serum and urine should be monitored.
It is necessary to monitor the level of uric acid in the blood serum when prescribing Isoprinosine in combination with drugs that increase the level of uric acid, or drugs that violate kidney function.
Influence on the ability to drive vehicles and other mechanisms.
Isoprinosine is a synthetic complex derivative of purine, which has immunostimulating activity and a non-specific antiviral effect.
The drug shows antiviral activity regarding viruses , CMV and measles virus, human T-cell lymphoma virus type III, polioviruses, influenza A and B, ESNO virus (human enterocytopathogenic virus), encephalomyocarditis and equine encephalitis. The mechanism of antiviral action of Isoprinosine is associated with the inhibition of viral RNA and the enzyme dihydropteroate synthetase, which is involved in the replication of some viruses, enhances the virus-suppressed synthesis of lymphocyte mRNA, which is accompanied by the suppression of viral RNA biosynthesis and translation of viral proteins, increases the production of interferons-alpha and gamma-by lymphocytes with antiviral properties. When combined, it increases the effect of interferon-alpha, antiviral agents acyclovir and zidovudine
the concentration of ingredients in the blood plasma is determined after 1-2 hours.
It is rapidly metabolized and excreted through the kidneys. It is metabolized similarly to endogenous purine nucleotides to form uric acid. N-N-dimethylamino-2-propranolone is metabolized to N-oxide, and para-acetamidobenzoate to o-acylglucuronide. No accumulation of the drug in the body was detected. T1/2
In a dry place, protected from light, at a temperature not exceeding 25 °C.
Shelf life of the drug Isoprinosine5 лет.Do not use after the expiration date indicated on the package.
| 1 table. | |
| inosine pranobex | |
| excipients: |
Tablets, 500 mg.
It is not recommended to use the drug during pregnancy and during lactation, because the safety of the use has not been studied.
Inside, after eating, wash down with a small amount of water.
The recommended dose for adults and children from 3 years of age (body weight from 15-20 kg) is 50 mg/kg / day, divided into 3-4 doses. Adults-6-8 tablets/day, children-1/2 table./5 kg/day. In severe forms of infectious diseases, the dose can be increased individually to 100 mg / kg / day, divided into 4-6 doses. The maximum daily dose for adults is 3-4 g / day, for children-50 mg / kg / day.
Duration of treatment
In acute diseases: the duration of treatment in adults and children is usually from 5 to 14 days. Treatment should be continued until the clinical symptoms disappear and for another 2 days in the absence of symptoms. If necessary, the duration of treatment can be increased individually under the supervision of a doctor.
In chronic recurrent diseases in adults and children treatment should be continued in several courses of 5-10 days with a break in the reception of 8 days.
For maintenance therapy, the dose can be reduced to 500-1000 mg per day (1-2 tablets) for 30 days.
In case of herpetic infection in adults and children prescribe for 5-10 days before the disappearance of symptoms of the disease, in the asymptomatic period-1 table. 2 times a day for 30 days to reduce the number of relapses.
With papillomavirus infection in adults the drug is prescribed 2 tablets. 3 times a day, for children-1/2 table./5 kg of body weight/a day in 3-4 doses for 14-28 days in the form of monotherapy.
With recurrent genital warts in adults the drug is prescribed 2 tablets. 3 times, for children-1/2 table./5 kg/day in 3-4 doses per day, either as monotherapy, or in combination with surgical treatment for 14-28 days, then with a three-time repetition of this course at intervals of 1 month.
For cervical dysplasia associated with the human papillomavirus, prescribe 2 tablets 3 times a day for 10 days, then conduct 2-3 similar courses with an interval of 10-14 days.
J05AX05 Inosine pranobex
